<\/p>\n
“Soft Tissue Sarcoma with Lung Metastasis Market<\/a><\/strong><\/span>” report has been added to DelveInsight<\/p>\n Soft Tissue Sarcoma with Lung Metastasis disease Overview<\/strong><\/p>\n Soft tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas).<\/p>\n Get Free sample copy- https:\/\/www.delveinsight.com\/sample-request\/soft-tissue-sarcoma-with-lung-metastases-market <\/a><\/span><\/strong><\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market: Geography Covered<\/strong><\/p>\n • The United States<\/p>\n • EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/p>\n • Japan<\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market Company<\/strong><\/p>\n Soft Tissue Sarcoma with Lung Metastasis Drug<\/strong><\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market Report<\/strong><\/a><\/span><\/p>\n Many STSs are associated with reciprocal translocations. Some forms of STS are associated with a variation (mutation) in a single oncogene, which is believed to drive the growth of cancer. An altered (mutation) oncogene may produce a protein that is ineffective, overproduced, or under-produced. Environmental factors that have been associated with STSs include radiation therapy and exposure to certain chemicals, including vinyl chloride, arsenic, and thorium dioxide.<\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market Research Report<\/strong><\/a><\/span><\/p>\n Although pulmonary metastases most commonly arise from primary tumors in the extremities, they may arise from almost any histologic variant or primary site. The most common site of distant spread of sarcomas is the lung. Thus, a new pulmonary nodule is likely to be metastatic if the primary malignancy was a sarcoma. Isolated pulmonary metastases occur in as many as 20% of patients diagnosed with soft tissue sarcoma as many as 40% in those with primary bone sarcoma. Metastases may infrequently occur in the skin, soft tissues, liver, and, in three percent of cases, the lymph nodes.<\/p>\n Soft Tissue Sarcoma with Lung Metastasis Treatment Market<\/strong><\/p>\n The development of pulmonary metastases has a negative impact on prognosis, with most of the untreated patients dying within 6–11 months from diagnosis. Chemotherapy remains the standard treatment in metastatic sarcomas, but when it is performed alone, it shows poor improvement in survival rates. On the other hand, surgical therapy seems to be effective in prolonging survival among patients with resectable disease, with 5-year survival rates ranging from 15–50.9%.<\/p>\n Soft Tissue Sarcoma with Lung Metastasis<\/strong> Market Research<\/strong><\/p>\n Metastasectomy and\/or chemotherapy are the most common treatments offered to patients with metastatic sarcoma. Pulmonary metastasectomy, either video-assisted or through a formal thoracotomy, has been shown to increase overall survival in select populations of both osseous and soft tissue sarcoma patients.<\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market Insights<\/strong><\/p>\n Once the systemic metastatic disease develops, the prognosis is typically poor. Patients with extremity sarcomas are more likely to develop the distant metastatic disease as the initial site of recurrence. In contrast, those with retroperitoneal and visceral sarcomas tend to present local recurrence. The lung is the most frequent site of metastasis from soft-tissue sarcomas. Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of pulmonary metastases has been a pivotal therapy in this disease.<\/p>\n Soft Tissue Sarcoma with Lung Metastasis Market Report Insights<\/strong><\/p>\n • Patient Population<\/p>\n • Therapeutic Approaches<\/p>\n • STS with lung metastases Pipeline Analysis<\/p>\n • STS with lung metastases Market Size and Trends<\/p>\n • Market Opportunities<\/p>\n • Impact of upcoming Therapies<\/p>\n <\/p>\n Get Free sample copy- https:\/\/www.delveinsight.com\/sample-request\/soft-tissue-sarcoma-with-lung-metastases-market <\/a><\/span><\/strong><\/p>\n <\/p>\n Table of content<\/strong><\/p>\n 1 Key Insights<\/p>\n 2 Executive Summary of STS with lung metastases<\/p>\n 3 STS with lung metastases Market Overview at a Glance<\/p>\n 4 Disease Background and Overview: STS with lung metastases<\/p>\n 5 Case Reports<\/p>\n 6 Epidemiology and Patient Population<\/p>\n 7 United States Epidemiology<\/p>\n 8 EU5 Epidemiology<\/p>\n 9 Japan Epidemiology<\/p>\n 10 Current Treatment and Medical Practices<\/p>\n 10.3 Treatment Algorithm<\/p>\n 11 Unmet needs<\/p>\n 12 Emerging Drugs<\/p>\n 13 Patient Journey<\/p>\n 14 STS with lung metastases: 7MM Analysis<\/p>\n 15 7MM Market Outlook<\/p>\n 16 United States<\/p>\n 17 EU-5 Countries<\/p>\n 18 Japan<\/p>\n 19 Market Drivers<\/p>\n 20 Market Barriers<\/p>\n 21 SWOT Analysis<\/p>\n 22 Recognized Establishments<\/p>\n 23 Appendix<\/p>\n 24 DelveInsight<\/strong> Capabilities<\/p>\n 25 Disclaimer<\/p>\n 26 About DelveInsight<\/strong><\/p>\n <\/strong><\/p>\n <\/strong><\/p>\n <\/p>\n <\/p>\n Media Contact<\/span>\n
\n
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> www.delveinsight.com\/<\/a><\/p>\n